Literature DB >> 17653920

Disease progression and survival in ALS: first multi-state model approach.

Juan Gil1, Pierre-Marie Preux, Ahmadou Alioum, Carlos Ketzoian, Jean-Claude Desport, Michel Druet-Cabanac, Philippe Couratier.   

Abstract

Although several prognostic factors have been identified in ALS, there remains some discordance concerning the prognostic significance of the age and clinical form at onset. In order to clarify these findings, we have analysed already known prognostic factors using a multi-state model. Two hundred and twenty-two sporadic ALS patients were followed. A simple unidirectional three-states model was used to summarize clinical course of ALS. States 1 and 2 reflected the progression of neurological impairment and state 3 represented the end of follow-up (tracheotomy or death). Gender, diagnostic delay, body mass index (BMI) and slow vital capacity (SVC) were also recorded. A time-inhomogeneous Markov model with piecewise constant transition intensities was used to estimate the effect of the covariates in each transition. The bulbar form at onset was only correlated with a more rapid clinical progression between state 1 and state 2. In contrast, an advanced age at diagnosis affected only survival from state 2. This methodological approach suggests that these two factors have a different prognostic significance: age at onset is related to patient's survival and the clinical form at onset predicts the progression of motoneuronal impairment in different regions.

Entities:  

Mesh:

Year:  2007        PMID: 17653920     DOI: 10.1080/17482960701278562

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  4 in total

Review 1.  Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology and survival.

Authors:  John D Beard; Freya Kamel
Journal:  Epidemiol Rev       Date:  2014-10-31       Impact factor: 6.222

2.  Kinetics methods for clinical epidemiology problems.

Authors:  Alexandru Dan Corlan; John Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

Review 3.  Kynurenine Pathway Metabolites as Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Vanessa X Tan; Gilles J Guillemin
Journal:  Front Neurosci       Date:  2019-09-20       Impact factor: 4.677

4.  Antecedent Disease and Amyotrophic Lateral Sclerosis: What Is Protecting Whom?

Authors:  Sabrina K Hollinger; Ike S Okosun; Cassie S Mitchell
Journal:  Front Neurol       Date:  2016-03-29       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.